EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network

☰ Menu

Aurelija Zvirbliene

Name of the laboratory

Department of Immunology and Cell Biology
Institute of Biotechnology, Life Sciences Center, Vilnius University
Sauletekio av. 7
LT-10257 Vilnius, Lithuania

Members of the laboratory

Members: Department of Immunology and Cell Biology
Unit Leader
Aurelija Zvirbliene
Research Fellows
Indre Kucinskaite-Kodze
Dovile Stravinskiene
PhD Students
Martynas Simanavicius

Laboratory activity

The Dept. of Immunology and Cell Biology is involved in the development and characterization of monoclonal antibodies (MAbs) since 1995. The Department is a part of the newly established Life Sciences Center of Vilnius University with an appropriate infrastructure for cell culture work, immunochemical analysis, molecular biology experiments.

We perform all steps of MAb development - from the generation of recombinant antigens to the detailed characterization of the MAbs including epitope mapping. We also produce recombinant antibodies in different formats.

The network of our international collaborations includes both academic and industrial partners.

Research activities

We have generated hundreds of MAbs against different targets: viral antigens, bacterial virulence factors, cellular proteins, cytokines, hormones, allergens, chemical compounds. The largest antibody collection is generated against viral antigens. These MAbs are valuable tools for investigating antigenic structure of viruses, development of diagnostic assays and prevalence studies of viral infections.

We combine antibody technologies with virus-like particle technologies.

For producing more efficient immunogens, we employ virus-like particles as a carrier for target epitopes to increase their immunogenicity. This approach provides possibilities to generate antibodies against short and non-immunogenic protein sequences.

For construction of recombinant antibodies, we use gene sequences encoding the variable parts of immunoglobulin heavy and light chains from hybridoma cells producing well-characterized MAbs. Recombinant antibodies are generated in different formats - as single-chain antibodies (scFv) and Fc-engineered antibodies where the scFv derived from hybridoma cells is joined to human IgG Fc fragment. Also, we employ recombinant virus-like particles as a carrier for antibody molecules, both scFv and Fc-engineered scFv. This innovative approach allows generation of recombinant multimeric antibodies displayed on virus-like particles.

A significant part of our MAbs are commercialized and/or included into diagnostic kits. We have contracts with industrial partners from Lithuania, UK, Germany, Finland, USA.

Techniques available

Publications (2014-present)

Patents (2010-Present)